SecBot SecBot
SECBOTREPLAY Home › Report › RCKT

RCKT · Rocket Pharmaceuticals announced a positive clinical safety update from…

ROCKET PHARMACEUTICALS, INC. · 8-K filed Aug 3, 2026 at 07:41 ET

At the news

BULLISHIMPACT 6/10

8-K filed Aug 3, 2026 at 07:41 ET

Rocket Pharmaceuticals announced a positive clinical safety update from the first three patients treated under the modified Phase 2 protocol for RP-A501 in Danon disease. No thrombotic microangiopathy (TMA), capillary leak syndrome, or other significant safety concerns were observed. The company is engaging with the FDA to align on the path to completing the pivotal trial, with a regulatory pathway update expected in H2 2026. This is an early, encouraging safety readout for a high-risk gene therapy program, but it does not include efficacy data or a definitive FDA agreement, limiting the near-term catalyst impact.

  • Initial three patients treated with RP-A501 under the modified Phase 2 protocol showed no TMA, capillary leak syndrome, or other significant safety concerns.
  • RP-A501 was well-tolerated at the recalibrated dose of 3.8 × 10^13 GC/kg with a refined immunomodulatory regimen.
  • Rocket is actively engaging with the FDA to align on the path to dosing additional patients and completing the 12-patient pivotal Phase 2 trial.
  • Regulatory pathway update and a comprehensive Danon disease program update are both expected in the second half of 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access